HC Wainwright Reiterates Buy Rating for Adlai Nortye (NASDAQ:ANL)

Adlai Nortye (NASDAQ:ANL)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Friday, MarketBeat reports. They presently have a $9.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 361.54% from the stock’s current price.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Adlai Nortye in a research report on Thursday, June 20th.

Adlai Nortye Stock Performance

NASDAQ:ANL opened at $1.95 on Friday. The stock’s fifty day moving average is $2.39 and its two-hundred day moving average is $5.68. Adlai Nortye has a 52 week low of $1.85 and a 52 week high of $17.48.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.